ContraVac's post-vasectomy home sperm test
This article was originally published in Clinica
Executive Summary
SpermCheck Vasectomy, a diagnostic which confirms men's post-vasectomy sterility, has been granted 510(k) clearance from the US FDA. The device, manufactured by Charlottesville, Virginia-based ContraVac, will enable men to test their fertility status at home, in a procedure the company describes as similar to a home pregnancy test for women. It is the first at-home diagnostic to receive FDA approval for sperm testing after vasectomy. SpermCheck Vasectomy is designed to improve the compliance rate for post-vasectomy sterility testing. Around 500,000 vasectomies are performed each year in the US and most patients are asked to undergo two post-vasectomy sperm tests. Currently, nearly 35% of patients never return to the doctor's surgery or lab for their first test and over 70% do not return for their second. The diagnostic will be launched in the US in mid-2008.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.